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Abstract: 
Bangladesh has made impressive economic and social progress in the past decade, despite frequent natural 
disasters and external shocks. The average GDP growth over the last five years was over 6%. In Bangladesh 
the pharmaceutical sector is one of the most developed hi-tech sectors within the country's economy. This 
sector is also providing about 97% of the total medicine requirement of the local market. But the financial 
progress of this industry is not satisfactory. Financial diagnosis indicates how well a company uses its 
assets, shareholders’ equity & liability, revenue and expenses. This study attempts to refer to judgment of 
financial health, strength and weakness of this industry by measuring its past, present and future financial 
performance and risks. In spite of satisfactory level of bankruptcy of the industry as found by The Z-Score 
Model, it was observed from the study that the liquidity, profitability and solvency position of most of the 
selected pharmaceuticals are in average position. The causal factors behind this position are unsound 
financial management, inadequate working capital, slow conversion of receivables and inventory into cash, 
lower position of sales, higher amount of debt, no professional distribution house, restrictions on patent 
right, fixed mark-up system, contrary policy of the government, vulnerability of environmental risk and 
increased cost of production. Therefore, the concerned authority should take immediate measures for 
overcoming these limitations. 
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1. Introduction:  
After the promulgation of Drug Control Ordinance-1982, the development of the pharmaceutical sector has 
accelerated. Among the various listed companies in Bangladesh pharmaceuticals are playing a vital role for 
the economical development and industrialization of the country. Due to recent development of this sector it 
is exporting medicines to global market. It earns a lot of foreign currency through exporting its products after 
meeting the domestic needs of the country’s health sector. The professional knowledge, thoughts and 
innovative ideas of the pharmaceutical professionals working in this sector are the key factors for these 
developments. Recently few new companies have been established with hi-tech equipments and qualified 
professionals which will enhance the strength of this industry. The company is subject to a process of 
decision-making which ensures its regulation to function normally. In case a disturbance appears within the 
company, steps will be taken in way of adopting some regulatory decisions, starting from the causes for the 
further development of the institution as well as the industry. This is where the diagnosis appears, with the 
role of identifying the causes that have offset the well being of the company. Financial diagnosis is a process 
of evaluating the relationship between component parts of financial statements to obtain a better 
understanding of the company’s position and performance. A short-term creditor will be interested in the 
current financial position of a company, while a long-term creditor will pay more attention to the solvency of 
the company. The long-term creditor will also be interested in the profitability of the company. The equity 
shareholders are generally concerned with their return. Performing a company diagnosis is done not only 
when the company is facing problems, but also when the evaluation of its performance is considered or when 
the company is in good health, but improvement is desired. The financial diagnosis can arise in various 
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situations, taking on various traits: It becomes a strategic diagnosis when it follows the company’s strengths 
and weaknesses, both in using its economic potential and in relation to the external business environment. It 
is elaborated as a stock-market diagnosis when it considers the relationship of the company with the stock 
market, if the company is quoted on the market. The indicators supplied by the diagnosis are an important 
element in guiding the purchase or sale of stock, both for the company and for the other investors in the stock 
market. It is a valuation diagnosis when it contributes to clarifying some necessary elements for establishing 
the value of a company, in case of investment, mergers, etc. The financial diagnosis can determine directly 
the patrimony value of the company or can supply the indicators necessary for establishing its yield value, 
because it allows the evaluation of the company’s durable beneficiary capacity, when it intervenes in order to 
determine the difficulties a company is facing and follows its stabilization, it is a crisis diagnosis. In this 
study, the priority of the diagnosis is to determine whether the selected pharmaceuticals are capable to 
maintain or to regain their short-term and long-term solvency with desirable profit margin. 
 
2. Objectives of the Study: 
The objectives of financial diagnosis are based on what is monitored within the company and are subordinate 
to the interests of the users. Generally, the financial diagnosis provides information regarding: how the 
company’s activities are carried out throughout the examined period and what is the growth rate compared to 
that of the sector; whether the results obtained are proportionate to resources used and whether the growth is 
accompanied by a satisfactory yield; what is the financial structure of the company and whether it is balanced 
or not, in the context of the ratio between the capital masses for a suitable financial support; whether the 
company has weaknesses and whether or not there is an increased bankruptcy risk. The study is designed to 
achieve the following objectives: 
 To diagnose financial performance of the selected pharmaceuticals.  
 To find out the interrelation among the short-term solvency, earning capacity and long- term 
solvency of the pharmaceutical industry. 
 To assess the future growth prospect of the selected pharmaceuticals. 
 To find out the limitations, if any, to the further development of the selected pharmaceuticals and 
taking corrective measures. 
 
3. Review of Related Studies: 
“Financial Statements are like a fine perfume to be sniffed but not swallowed.” - Abraham Brillofff. Altman 
(1968) used financial ratios with The Z-Score Model to predict corporate bankruptcy. He observed that the 
model is very successful in predicting failed and non-failed firms. Hannan and Shaheed (1979) used financial 
ratios to examine the financial position and performance of Bangladesh Shilpa Bank. They revealed that 
techniques of financial analysis can be used in the evaluation of financial position and performance of 
financial institution as well as non-financial institutions even Development Financial Institutions (DFI). 
Ohlson (1980) used financial ratios to predict a firm’s crisis. He found that there are four factors affecting a 
firm’s vulnerability. These factors are the firm’s scale, financial structure, performance and liquidity. Khan 
(1991) suggested ratio analysis as the tool for the evaluation of the financial performance of the particular 
organization. Mina & Taleb (1995) summarized that the analysis and interpretation of financial statements 
are generally aimed at determining the financial position of a firm. Financial ratio was used as an analytical 
technique for assessing the performance of the concern. Jahur and Mohiuddin (1995) used financial ratios to 
measure operational performance of a limited company. They used profitability, liquidity, activity and capital 
structure ratios to measure operational performance. Jahur and Parveen (1996) used Altman’s MDA Model to 
conclude the bankruptcy position of Chittagong Steel Mills Ltd. They found that the absence of realistic goals 
and strict Govt. regulations are the main reasons for the lowest level of bankruptcy. Bala & Habib (1997) 
suggested that ratio analysis can be used for the performance evaluation of the financial institutions. They 
also used portfolio theories for calculating NAV (Net Asset Value) of mutual funds. Hye & Rahman (1997) 
performed a research to assess the performance of the selected private sector general insurance companies in 
Bangladesh. The study revealed that the private sector insurance companies had made substantial progress 
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and were keeping their surplus funds in the form of fixed deposits with different commercial banks due to 
absence of suitable opportunities for investment. Sina and Ali (1998) used financial ratios to test the financial 
strengths and weaknesses of Khulna Newsprint Mills Ltd. They found that due to lack of planning and control 
of working capital, operational inefficiency, obsolete store, ineffective credit policy, increased cost of raw 
materials, labor and overhead, the position of the company was not good. In the article “The Assessment of 
Financial and Operating Performance of the Cement Industry: A Case Study of Confidence Cement 
Limited”, Dutta and Bhattacharjee (2001) found that the investment in cement industry was fairly profitable. 
Salauddin (2001) examined the profitability of the pharmaceutical companies of Bangladesh. By adopting 
ratio analysis, mean, standard deviation and co-efficient of variation, he found that the profitability of the 
pharmaceutical sector was very satisfactory in terms of the standard norms of return on investment. 
Wen-Cheng LIN et. al (2005) stated financial ratios as the simplest tools for evaluating the financial 
performance of the firm. One can use financial ratios to determine a firm’s liquidity, profitability, solvency 
and capital structure. Reilly and Brown (2005) stated that financial statement analysis seeks to evaluate 
managerial performance in several important areas including profitability, efficiency and risk. The ultimate 
goal of that analysis is to provide insights that will help us project future managerial performance. They also 
suggest that financial ratios should be examined relating to the economy, the firm’s industry, firm’s main 
competitors and the firm’s past relative ratios. Islam, Farzana and Rahman (2009) conducted a research on 
financial diagnosis of the financial institutions of Bangladesh: A comparative study on IPDC, IDLC and ICB 
and through ratio analysis they measured the financial health of the financial institutions and concluded that 
financial institutions play a key role in the economic development of capital market of the country. Hassan 
and Habib (2010) used financial ratios for conducting a research on performance evaluation of the 
pharmaceutical companies in Bangladesh. They revealed that the financial performance of Beximco 
Pharmaceuticals Ltd. is better than Square Pharmaceuticals Ltd. Majumder and Rahman (2011) used 
financial ratios and Prof. Altman’s MDA Model (The Z-Score Model) for financial analysis of selected 
pharmaceutical companies in Bangladesh. They observed from the study that the profitability, liquidity and 
solvency position of the selected pharmaceuticals are not in sound position and it was also observed that most 
of the selected pharmaceuticals have a lower level position of bankruptcy. These reviews provide that for the 
overall financial diagnosis of the selected listed pharmaceutical companies in Bangladesh, ratio analysis and 
Professor Altman’s The Z-Score Model are the most fruitful techniques. In this study financial diagnosis is 
made for the five selected listed pharmaceutical companies in Bangladesh for a period of three years from 
2006-2007 to 2008-2009.  
 
4. Hypothesis: 
The research is conducted on the basis of the following hypotheses:  
H0: The difference between the industry and the individual pharmaceutical’s mean ratio is not significant.  
H1: The difference between the industry and the individual pharmaceutical’s mean ratio is significant.  
The hypotheses are tested at the 5% level of significance (Two-tailed). 
 
5. Methodology of the Study: 
We have collected the data from a random sample of five listed pharmaceutical companies which are 
enlisted both in Dhaka Stock Exchange Ltd. and Chittagong Stock Exchange Ltd. of Bangladesh. The study 
is based on a three year period from 2006-2007 to 2008-2009. Both primary as well as secondary sources of 
information have been considered as a data collection process. The secondary information of the study was 
collected from the websites, published literature, research papers and various reports of the sample 
pharmaceuticals. The primary data was collected through personal interview and discussions with the 
concerned executives of the selected pharmaceuticals. These data have been tabulated, analyzed and 
interpreted with the help of different financial ratios, statistical tools like mean, standard deviation, 
coefficient of variation, coefficient of correlation, T- test and The Z-Score Model. The hypotheses are tested 
through statistical measurement to arrive at systematic conclusion and contribute to the further development 
of research work regarding same perspective. 
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6. Analysis and Results: 
The ratio analysis is the most powerful tool of financial diagnosis of a company or an industry. It can be 
used to compare the risk and return relationships of the companies of different sizes. The term ratio refers 
to the numerical or quantitative relationship between two items or variables. This relationship can be 
expressed as percentages, fraction and proportion of numbers. Many diverse groups of people (shareholders, 
creditors, investors, management etc.) are interested in analyzing the financial information to know about 
the operating and financial efficiency and growth of the company. 
 
6.1 Liquidity ratios: 
Liquidity is the ability of a company to readily and easily obtain cash from its asset in order to meet its 
short-term obligations or make purchase. This is done by comparing a company’s most liquid assets (or 
those that can be easily converted to cash) to its short-term liabilities. In general the greater the coverage of 
liquid assets to short term liabilities the better as it is a clear signal that a company can pay its debts that is 
coming due in near future and still funds its ongoing operations. On the other hand, a company with a lower 
coverage rate should raise a red flag for investors as it may be a sign that the company will have difficulty 
to meet its operational as well as short-term obligations. 
 
6.1.1 Current Ratio [CR]: 
The current ratio is a popular financial ratio used to test a company’s liquidity by deriving the proportion of 
current assets available to cover current liabilities. The concept behind this ratio is to ascertain whether a 
company’s short term assets (cash, cash equivalent, marketable securities, receivable, inventory etc.) are 
readily available to pay off its short term liabilities (notes payable, current portion of term debt, payables, 
accrued expenses, taxes etc.). It is computed by dividing current assets by current liabilities. Generally 2:1 is 
considered as the standard norm for current ratio. If the ratio is too low, the company may face difficulty in 
meeting the short term debt. If the ratio is too high, the company may have an excessive investment in current 
assets. As the Table-01 depicts that, the industry average of current ratio is 1.130:1 which indicates that the 
industry is able to meet its current obligations from its current assets. The average current ratio varies from 
0.752:1 in ISPIL to 1.960:1 in BPL. The average of ISPIL-0.752:1, LIL-0.781:1 and OIL-0.771:1 is below 
from the industry average and also from the standard norm. The average of SPL-1.387:1, BPL-1.960:1 is 
above from the industry average but below from the standard norm. It is observed from the Table-01 that in 
case of SPL, BPL, ISPIL, LIL and OIL the current ratio of the income year 2006-2007, 2007-2008 and 
2008-2009 are 1.440:1, 1.260:1, 1.460:1;  1.800:1, 1.100:1, 2.980:1; 0.694:1, 0.832:1, 0.730:1; 0.814:1, 
0.840:1, 0.690:1 and 0.706:1, 0.825:1, 0.782:1 respectively. It can be said from the study that the liquidity 
position of the most of the selected pharmaceuticals is not satisfactory to meet its short-term obligations. 
From the Table-01 it is seen that the CR of the selected pharmaceuticals is less stable (CV: SPL-7.947%, 
BPL-48.48%, ISPIL-9.548%, LIL-10.24% and OIL-7.782%). From the calculated value of t, it is found that, 
there is a significant difference in current ratio between industry average and ISPIL, LIL and OIL. On the 
other hand there lies an insignificant difference in current ratio between industry average and SPL and BPL. 
6.1.2 The Quick/Liquid/Acid-Test Ratio [ATR]: 
It is a liquidity indicator that further refines the current ratio by measuring the amount of the most liquid 
current assets available to cover current liabilities. The quick ratio is more conservative than the current ratio 
because it excludes inventory and other current assets which are more difficult to turn into cash. Acid-Test or 
quick ratio measures the company’s immediate short-term liquidity. It is computed by dividing the sum of 
cash, short-term investments and net receivables by current liabilities. In this ratio, 1:1 is considered as the 
standard norm. The Table-02 shows that the industry average of ATR is 0.512:1. The average ATR of 
SPL-0.677:1 and BPL-1.158:1 is above from the industry average but here, only BPL-1.158:1 is above from 
the standard norm and SPL-0.677:1 is under the standard norm. The average of ISPIL-0.253:1, LIL-0.213:1 
and OIL-0.262:1 is below from the industry average as well as the standard norm. It indicates that the selected 
pharmaceuticals except BPL are unable to pay immediate short term liabilities. It is observed from the 
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Table-02 that in case of SPL, BPL, ISPIL, LIL and OIL the ATR of the income year 2006-2007, 2007-2008 
and 2008-2009 are 0.790:1, 0.630:1, 0.610:1; 0.763:1, 0.500:1, 2.210:1; 0.170:1, 0.323:1, 0.265:1; 0.217:1, 
0.216:1, 0.205:1 and 0.192:1, 0.313:1, 0.282:1 respectively. From the Table-02 it is clear that the ATR of the 
selected pharmaceuticals is less stable (CV: SPL-14.56%, BPL-79.54%, ISPIL-30.68%, LIL-3.130% and 
OIL-23.94%). From the calculated value of t, it is observed that there is a significant difference in ATR 
between industry average and ISPIL, LIL and OIL. On the other hand there lies an insignificant difference in 
ATR between industry average and SPL and BPL. 
 
6.1.3 Receivables Turnover [RT]: 
The ratio used to assess the liquidity of the receivables is called receivables turnover. It measures the number 
of Times on average the company collects receivables during the period. The higher receivables turnover 
indicates the better performance of the company. The Table-03 shows that the industry mean of RT is 525.2 
Times. The average RT varies from 7.390 times in BPL to 2569 Times in ISPIL. But the Table-03 shows that, 
there is an exceptional average RT of 2569 Times in the ISPIL as compare to other selected pharmaceuticals. 
The average RT of the selected pharmaceuticals except ISPIL is below from the industry average. It is 
observed from the Table-03 that in case of SPL, BPL, ISPIL, LIL and OIL the RT of the income year 
2006-2007, 2007-2008 and 2008-2009 are 23.23, 22.92, 20.56; 7.199, 7.958, 7.014; 4468, 1760, 1479; 14.56, 
23.85, 12.26 and 10.91, 10.35, 10.73 Times respectively. It is observed from Table-03 that the RT of ISPIL 
and LIL is less stable than SPL, BPL and OIL (CV: SPL-6.567%, BPL-6.786%, ISPIL-64.25%, LIL-36.33% 
and OIL-2.681%). From the calculated value of t, it is found that there is a significant difference in RT 
between industry average and SPL, BPL, LIL and OIL. On the other hand there lies an insignificant 
difference in RT between industry average and ISPIL. 
 
6.1.4 Inventory Turnover [IT]: 
Inventory turnover measures the number of Times, on average, the inventory is sold during the period. The 
purpose of inventory turnover is to measure the liquidity of the inventory. It is computed by dividing cost of 
goods sold by the average inventory. Unless seasonal factors are significant, beginning and ending inventory 
balances are considered to compute average inventory. Some authors consider the standard figure of 
inventory turnover is 8 Times. The Table-04 shows that the industry average of IT is 4.471 Times. The 
average IT varies from 1.367 Times in BPL to 11.01 Times in ISPIL. Only the average of ISPIL-11.01 is 
above from the industry average. It is observed from the Table-04 that in case of SPL, BPL, ISPIL, LIL and 
OIL the IT of the income year 2006-2007, 2007-2008 and 2008-2009 are 2.960, 2.720, 2.750; 1.200, 1.300, 
1.600; 9.150, 11.02, 12.85; 3.920, 5.190, 3.510 and 2.480, 3.334, 3.077 Times respectively. The Table-04 
shows that the IT of the selected pharmaceuticals is less stable (CV: SPL-4.655%, BPL-15.23%, 
ISPIL-16.81%, LIL-20.82% and OIL-14.78%). From the calculated value of t, it is found that there is a 
significant difference in IT between industry average and SPL, BPL, ISPIL and OIL. On the other hand there 
lies an insignificant difference in IT between industry average and LIL. 
 
6.2 Profitability Ratios: 
Profitability is one measurement of how successful a company is. The more profitable the company, the 
more money the company is making. Profitability refers to a company’s ability to generate an adequate 
return on invested capital. Return is judged by assessing earnings relative to the level and sources of 
financing. Profitability is also relevant to solvency. Profitability ratios measure the income or operating 
success of a company for a given period of time. Income or lack of it, affects the company’s ability to 
obtain debt and equity financing. It also affects the company’s liquidity position and the company’s ability 
to grow. As a consequence, both creditors and investors are interested in evaluating earning power or 
profitability. Analysts frequently use profitability as the ultimate test of management’s operating 
effectiveness.  
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6.2.1 Profit Margin [PM]: 
Profit margin is a measure of the percentage of each Taka of sales that results in net income. It is computed by 
dividing net income by net sales. The profit margin must be positive and some authors consider the standard 
figure of PM is 5%-10%. As the Table-05 shows that the industry average of PM is 8.158%. The average PM 
varies from 1.557% in LIL to 17.67% in SPL. The average of SPL-17.67% and BPL-12.07% are above from 
the industry average. The average of ISPIL-3.837%, LIL-1.557% and OIL-5.662% are below from the 
industry average. It is observed from the Table-05 that in case of SPL, BPL, ISPIL, LIL and OIL the PM of 
the income year 2006-2007, 2007-2008 and 2008-2009 are 17.00%, 17.00%, 19.00% ; 9.800%, 13.60%; 
12.80%; 3.550%, 4.110%, 3.850%; 1.930%, 1.550%, 1.190% and 3.940%, 7.507% , 5.539% respectively. 
The Table-05 shows that the PM of the selected pharmaceuticals is less stable (CV: SPL-6.536%, 
BPL-16.60%, ISPIL-7.303%, LIL-23.77% and OIL-31.56%). From the calculated value of t, it is found that 
there is a significant difference in PM between industry average and SPL, ISPIL and LIL. On the other hand 
there lies an insignificant difference in PM between industry average and BPL and OIL. 
 
6.2.2 Asset Turnover [AT]: 
Asset turnover measures how efficiently a company uses its assets to generate sales. It is determined by 
dividing net sales by average assets. The resulting number shows the Taka of sales produced by each Taka 
invested in assets. Some authors consider the standard figure of asset turnover is 2 Times. The Table-06 
shows that the industry mean of AT is 1.020 times. The average AT varies from 0.293 Times in BPL to 2.253 
Times in ISPIL. The average AT of ISPIL-2.253 and LIL-1.193 are above from the industry average. On the 
other hand, the average of SPL-0.743, BPL-0.293 and OIL-0.619 Times are less from the industry average. It 
is observed from the Table-06 that in case of SPL, BPL, ISPIL, LIL and OIL the AT of the income year 
2006-2007, 2007-2008 and 2008-2009 are 0.760, 0.710, 0.760; 0.300, 0.299, 0.280; 2.160, 2.310, 2.290; 
1.170, 1.400, 1.010 and 0.480, 0.699, 0.677 Times respectively. It is seen from the Table-06 that the AT of 
the selected pharmaceuticals is less stable (CV: SPL-3.928%, BPL-3.413%, ISPIL-3.604%, LIL-16.43% and 
OIL-19.46%). From the calculated value of t, it is observed that there is a significant difference in AT 
between industry average and SPL, BPL, ISPIL and OIL. On the other hand there lies an insignificant 
difference in AT between industry average and LIL. 
 
6.2.3 Return on Asset [ROA]: 
An overall measure of profitability is return on asset. We compute this ratio by dividing net income by 
average assets. The return on asset must be positive and some authors consider the standard figure of ROA is 
10%-12%. The Table-07 shows that the industry average of ROA is 6.208%. The average varies from 
1.877% in LIL to 13.33% in SPL. The average of SPL-13.33% and ISPIL-8.653% are above from the 
industry average. On the other hand, the average of BPL-3.553%, LIL-1.877% and OIL-3.623 are below 
from the industry average. It is observed from the Table-07 that in case of SPL, BPL, ISPIL, LIL and OIL the 
ROA of the income year 2006-2007, 2007-2008 and 2008-2009 are 13.00%, 12.00%, 15.00%; 2.960%, 
4.100%, 3.600%; 7.650%, 9.500%, 8.810%; 2.260%, 2.170%, 1.200% and 1.870%, 5.250%, 3.749% 
respectively. The Table-07 shows that the ROA of the selected pharmaceuticals is less stable (CV: 
SPL-11.46%, BPL-16.08%, ISPIL-10.80%, LIL-31.32% and OIL-46.74%). From the calculated value of t, it 
is found that there are significant differences between industry average and SPL, BPL, ISPIL, LIL except 
OIL. 
 
6.2.4 Return on Common Stockholder’s Equity [ROCSE]: 
Another widely used profitability ratio is return on common stockholders’ equity. It measures profitability 
from the common stockholders’ point of view. This ratio shows how many Taka of net income the company 
earned for each Taka invested by the owners’. This is the most used profitability ratio which measures 
profitability of owners’ investment. It is computed by dividing net income by average common stockholders’ 
equity. As the Table-08 shows that the industry average of return on common stockholders’ equity is 13.26%. 
The average ROCSE varies from 5.353% in BPL to 21.92% in ISPIL. The average ROCSE of BPL-5.353%, 
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LIL-6.933% and OIL-12.76% are below from the industry average and the average ROCSE of SPL-19.33%, 
ISPIL-21.92% are above from the industry average. It is observed from the Table-08 that in case of SPL, 
BPL, ISPIL, LIL and OIL the ROCSE of the income year 2006-2007, 2007-2008 and 2008-2009 are 19.00%, 
18.00%, 21.00%; 4.360%, 5.800%, 5.900%; 16.98%, 24.40%, 24.37%; 7.840%, 7.830%, 5.130% and 
6.751%, 18.61%, 12.91% respectively. It can be observed from the Table-08 that the ROCSE of the selected 
pharmaceuticals is less stable (CV: SPL-7.901%, BPL-16.10%, ISPIL-19.51%, LIL-22.53% and 
OIL-46.49%). From the calculated value of t, it is found that there is a significant difference in ROCSE 
between industry average and SPL, BPL and LIL. On the other hand there lies an insignificant difference in 
ROCSE between industry average and ISPIL and OIL. 
 
6.2.5 Earnings Per Share [EPS]: 
Earnings per share are measure of the net income earned on each share of common stock. A measure of net 
income earned on a per share basis provides a useful perspective for determining profitability. EPS is 
measured by dividing net income by the number of weighted average common shares outstanding during the 
year. The Table-09 shows that the industry average of EPS is Tk. 56.52. The average EPS varies from Tk. 
3.847 in BPL to Tk. 176.60 in SPL. The average EPS of SPL-Tk. 176.60 is above from the industry average. 
On the other hand, the average EPS of BPL-Tk. 3.847, ISPIL-Tk. 44.66, LIL-Tk. 44.77 and OIL-Tk. 12.74 
are below from the industry average. It is observed from the Table-09 that in case of SPL, BPL, ISPIL, LIL 
and OIL the EPS of the income year 2006-2007, 2007-2008 and 2008-2009 are Tk. 218.6, Tk. 154.5, 
Tk.156.6; Tk. 3.080, Tk. 4.330, Tk. 4.130; Tk. 31.19, Tk. 48.09, Tk. 54.70; Tk. 48.14, Tk. 51.25, Tk. 34.93 
and Tk. 6.750, Tk. 18.61, Tk. 12.87 respectively. It can be found from the Table-09 that the EPS of the 
selected pharmaceuticals is less stable (CV: SPL-20.63%, BPL-17.46%, ISPIL-27.15%, LIL-19.35% and 
OIL-46.54%). From the calculated value of t, it is found that there is a significant difference in EPS between 
industry average and SPL, BPL and OIL. And there lies an insignificant difference in EPS between industry 
average and ISPIL and LIL. 
 
6.2.6 Price-Earnings Ratio [P-E]: 
The price-earnings ratio is an oft-quoted measure of the ratio of the market price of each share of common 
stock to the earnings per share. The price earnings ratio reflects investor’s assessments of a company’s future 
earnings. The P-E ratio is usually used to assess the owners’ appraisal of share value. It measures the amount 
that investors are willing to pay for each Taka of a firm’s earnings. The level of this ratio indicates the degree 
of confidence that investors have in the firm’s future performance. The higher is the ratio, the greater the 
investor’s confidence and vice versa. But from the profitability point of view the lower the ratio, the greater 
the investor’s short-term gain. The P-E ratio is calculated by dividing the market price per share of stock by 
earnings per share. As the Table-10 shows that the industry average of P-E is 24.33 Times. The average P-E 
varies from 17.85 Times in OIL to 31.86 Times in BPL. The average P-E of SPL-18.85 and OIL-17.85 are 
below from the industry average. On the other hand, the average P-E of BPL-31.86, ISPIL-24.77 and 
LIL-28.35 are above from the industry average. It is observed from the Table-10 that in case of SPL, BPL, 
ISPIL, LIL and OIL the P-E of the income year 2006-2007, 2007-2008 and 2008-2009 are 11.19, 26.60, 
18.75; 19.12, 38.73, 37.72; 25.22, 20.71, 28.38; 11.00, 28.24, 45.81 and 13.37, 8.080, 32.09 Times 
respectively. The Table-10 shows that the P-E of the selected pharmaceuticals is less stable (CV: 
SPL-40.89%, BPL-34.67%, ISPIL-15.56%, LIL-61.39% and OIL-70.69%). From the calculated value of t, it 
is found that there is an insignificant difference in P-E between industry average and the pharmaceuticals 
SPL, BPL, ISPIL, LIL and OIL. 
 
6.2.7 Payout Ratio [POR]: 
The payout ratio measures the percentage of earnings distributed in form of cash dividends. Companies that 
have high growth rates generally have low payout ratios because they reinvest most of their net income into 
the business. It is computed by dividing cash dividends by net income. The Table-11 shows that, the industry 
average POR is 48.67%. The average POR differs from 37.81% in LIL to 58.66% in ISPIL. The average POR 
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of SPL-45.26% and LIL-37.81% are below from the industry average. On the other hand, the average POR of 
BPL-51.33%, ISPIL-58.66% and OIL-50.29% are above from the industry average. It is observed from the 
Table-11 that in case of SPL, BPL, ISPIL, LIL and OIL the POR of the income year 2006-2007, 2007-2008 
and 2008-2009 are 45.74%, 48.53%, 41.52% ; 48.70%, 69.28%, 36.32%; 73.74%, 51.98%, 50.27%; 36.35%, 
34.15%, 42.94% and 0.000%, 53.73%, 97.13% respectively. It is observed from the Table-11 that the POR of 
the selected pharmaceuticals is less stable (CV: SPL-7.797%, BPL-32.43%, ISPIL-22.23%, LIL-12.10% and 
OIL-96.76%). From the calculated value of t, it is found that there is an insignificant difference in POR 
between industry average and the pharmaceuticals SPL, BPL, ISPIL, LIL and OIL. 
 
6.3 Solvency Ratios: 
Solvency is the ability of a business to have enough assets to cover its liabilities. Solvency is often 
confused with liquidity but it is not the same thing. Solvency ratio measures the ability of the company to 
service over a long period of time. Solvency is a necessary condition for a business to operate. If a company 
is unable to meet its obligation, it is said to be insolvent and must undergo bankruptcy in order to either 
liquidate or bankruptcy restructure. It provides a measurement of how lively a company will be to continue 
meeting its debt obligations. Long-term creditors and stockholders are particularly interested in a 
company’s ability to pay interest as it comes due to repay the face value of debt at maturity.  
 
6.3.1 Debt to Total Assets [DTA]: 
This ratio shows the percentage of assets that are being financed by creditors (instead of business owners). 
Generally no more than 50% of your assets should be financed by debt. You can reduce this ratio by paying 
off debt or increasing the value of your assets. It is computed by dividing total debt by total assets. The degree 
of leverage of the companies is indicated by this ratio. The higher the percentage of debt to total assets, the 
greater the risk that the company may be unable to meet its maturing obligations and vice versa is also true. 
The Table-12 shows that, the industry average of DTA is 53.81%. The average DTA varies from 29.67% in 
SPL to 74.73% in LIL. The average DTA of SPL-29.67% and BPL-35.26% are below from the industry 
average. On the other hand, the average DTA of ISPIL-61.72%, LIL-74.73% and OIL-67.71% are above 
from the industry average. The Table-12 shows that, in case of SPL, BPL, ISPIL, LIL and OIL the DTA of 
the income year 2006-07, 2007-08, 2008-09 are 30.00%, 34.00%, 25.00%; 30.97%, 29.50% 45.30%; 
57.54%, 63.27%, 64.34%; 72.00%, 72.49%, 79.69% and 70.92%, 67.27%, 64.93% respectively. It is 
observed from the Table-12 that the DTA of the selected pharmaceuticals is less stable (CV: SPL-15.20%, 
BPL-24.76%, ISPIL-5.925%, LIL-5.761% and OIL-4.459%). From the calculated value of t, it is found that, 
there is a significant difference in DTA between industry average and SPL, LIL and OIL. On the other hand, 
there lies an insignificant difference in DTA between industry average and BPL and ISPIL. 
 
6.3.2 Times Interest Earned [TIE]: 
Times interest earned, sometimes which is called, interest coverage ratio provides an indication of the 
company’s ability to meet interest payment as they come due. It is computed by dividing income before 
interest expense and income taxes by interest expense. The higher is the value, the better the ability of the 
firm to fulfill its interest obligations. The Table-13 shows that the industry average of TIE is 5.657 Times. 
The average TIE varies from 1.433 Times in LIL to 14.25 Times in ISPIL. The average TIE of BPL-3.483, 
LIL-1.433 and OIL-1.818 are below from the industry average. On the other hand, the average TIE of 
SPL-7.30 and ISPIL-14.25 are above from the industry average. It is observed from the Table-13 that in case 
of SPL, BPL, ISPIL, LIL and OIL the TIE of the income year 2006-2007, 2007-2008 and 2008-2009 are 
8.270, 6.310, 7.320; 2.600, 3.860, 3.990; 17.36, 12.40, 12.99; 1.500, 1.500, 1.300 and 1.402, 2.180, 1.872 
Times respectively. From the Table-13 it is found that the TIE of the selected pharmaceuticals is less stable 
(CV: SPL-13.43%, BPL-22.04%, ISPIL-19.01%, LIL-8.060% and OIL-21.55%). From the calculated value 
of t, it is found that there is a significant difference in TIE between industry average and BPL, ISPIL, LIL and 
OIL. On the other hand there lies an insignificant difference in TIE between industry average and SPL. 
 
European Journal of Business and Management     www.iiste.org 
ISSN 2222-1905 (Paper) ISSN 2222-2839 (Online) 
Vol 4, No.4, 2012 
78 
7. Sustainable Growth Analysis: 
The sustainable growth rate is a measure of how much a company can grow without borrowing more money. 
After the company has passed this rate, it must borrow fund from another source to facilitate growth. In other 
words, the maximum growth rate that a company can sustain without having to increase financial leverage. It 
is calculated as: ROE X (1 - Dividend Payout Ratio). Dividend payout ratio is calculated by dividing dividend 
per share by the earnings per share and ROE i.e., return on equity is calculated by dividing net income by the 
common stockholders’ equity. Analysis of company’s growth potential is important for both lenders and 
owners. The more a company reinvests, the greater it’s potential for growth. The Table-14 represents the 
sustainable growth rates as well as average growth rates of the sample pharmaceuticals for the study period. It 
is seen that the sustainable growth rates of the selected pharmaceuticals are fluctuating from year to year. 
From the Table-14 it is observed that SPL-10.62 and ISPIL-9.433 have a higher ratio as compared to industry 
average-6.451. So it can be said that growth in these two pharmaceuticals are quite satisfactory. On the other 
hand, BPL-2.593, LIL-4.360 and OIL-5.244 have a ratio lower than the industry average which indicates 
poor growth. It is also observed from the Table-14 that in case of SPL, BPL, ISPIL, LIL and OIL the 
sustainable growth rate of the income year 2006-2007, 2007-2008 and 2008-2009 are 10.31%, 9.265%, 
12.28%; 2.237%, 1.782%, 3.760%; 4.460%, 11.72%, 12.12%; 4.990%, 5.160%, 2.930% and 6.750%, 
8.611%, 0.371% respectively. It is appeared from the Table-14 that OIL has the highest variation-82.41% and 
ISPIL has the second highest variation-45.71% which indicates extremely instability in their growth (CV: 
SPL-14.42%, BPL-39.95%, ISPIL-45.71%, LIL-28.47% and OIL-82.41%). From the calculated value of t, it 
is observed that there is a significant difference in sustainable growth rate between industry average and SPL 
and BPL. On the other hand there lies an insignificant difference in sustainable growth rate between industry 
average and ISPIL, LIL and OIL. 
 
8. The Z-Score Model: Financial Soundness of the Selected Pharmaceuticals: 
The Z-Score Model for predicting bankruptcy was published in 1968 by Edward I. Altman, who was, at the 
time, an Assistant Professor of Finance at New York University. Edward I. Altman (born 1941) is a Professor 
of Finance at New York University`s Stern School of Business. He is best known for the development of The 
Z-Score Model for predicting bankruptcy. Dr. Altman was inducted into the Fixed Income Society's Hall of 
Fame in 2001 and was amongst the inaugural inductees into the Turnaround Management's Hall of Fame in 
2008. He was named one of the "100 Most Influential People in Finance" by the Treasury & Risk 
Management magazine in 2005. The Z-Score Model can provide a significant idea about the financial 
soundness of the selected pharmaceuticals. 
The number produced by the Model is referred to as the company's Z-Score, to represent the likelihood of a 
company going bankrupt in the next two years. The Z-Score Model uses multiple corporate income and 
balance sheet values to measure the financial health of a company. It is a linear combination of five common 
business ratios, weighted by coefficients. It is proven to be very accurate to forecast bankruptcy in a wide 
variety of contexts and markets. Studies show that the model has 72%-80% reliability of predicting 
bankruptcy. However, The Z-Score Model does not apply to every situation. It can only be used for 
forecasting if a company being analyzed can be compared to the database. It utilizes seven pieces of data 
taken from the corporation’s balance sheet and income statement. Five ratios are then extrapolated from these 
data points. To calculate the Z-Score, the results of each of the above five ratios are multiplied by a set factor 
(i.e. a coefficient developed by Professor Altman). The results of these multiplication are then added together 
to determine the company’s Z-Score. 
The Model is specified as:  
Z = 1.2A + 1.4B + 3.3C + 0.6D + 1.0E 
Where: 
Z = Score. 
A = Working Capital/Total Assets. 
B = Retained Earnings/Total Assets. 
C = Earnings before Interest & Taxes/Total Assets.  
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D = Market Value of Equity/Total Liabilities.  
E = Sales/Total Assets. 
The higher is the score, the healthier the company. It is a good idea to compare a company’s Z-Scores over 
time to get a better idea as to how the company is doing. The lower the Z-Score, the more likely a company 
is to go bankrupt. A Z-Score lower than 1.8 indicates that bankruptcy is likely, while scores greater than 3.0 
indicate bankruptcy is unlikely to occur in the next two years. Companies that have a Z-Score between 1.8 
and 3.0 are in the gray area (safety zone); bankruptcy is not easily predicted one way or the other. 
The Table-15 shows year-wise as well as average position of the ratios of working capital to total assets, 
retained earnings to total assets, earnings before interest and taxes to total assets, market value of equity to 
total debt and sales to total assets. From the Table-15 it is seen that the average positions for the income 
year 2006-2007, 2007-2008 and 2008-2009 of the working capital to total assets ratios are 0.090, 0.119, 
(0.133), (0.101), (0.078) Times, the retained earnings to total assets ratios are 0.360, 0.253, 0.047, 0.094, 
0.269 Times, the earnings before interest and taxes to total assets are 0.193, 0.058, 0.107, 0.081, 0.082 
Times, the sales to total assets are 0.703, 0.270, 2.053, 1.105, 0.625 Times for SPL, BPL, ISPIL, LIL and 
OIL respectively. On the other hand, the average market value of equity to total debt for the income year 
2006-2007, 2007-2008 and 2008-2009 is 7.980, 3.087, 3.147, 0.578 and 0.961 Times for SPL, BPL, ISPIL, 
LIL and OIL respectively. From the coefficient of variation in the Table-15, it is observed that the above 
ratios of the selected pharmaceuticals are less stable. 
The Table-16 shows the year-wise as well as the average position of Z-Score of the sample pharmaceuticals 
during the study period. After putting the respective values of A, B, C, D and E, in the aforesaid equation as 
developed by Prof. Altman, Z-Score was estimated. Average Z-Score of sample pharmaceuticals SPL-6.741 
and ISPIL-4.199 are higher than the industry average-3.447 as well as the solvency range provided by Prof. 
Altman. On the other hand, average Z-Score of BPL-2.809 is lower than the industry average but exists 
within the safety range provided by Prof. Altman but average Z score of LIL-1.729, OIL-1.754 are lower 
than the industry average and shows the position of bankruptcy. It is observed from the Table-16 that in 
case of SPL, BPL, ISPIL, LIL and OIL the Z-Score of the income year 2006-2007, 2007-2008 and 
2008-2009 is 4.719, 6.919, 8.586; 2.065, 3.782, 2.581; 3.998, 4.017, 4.581; 1.624, 2.201, 1.363 and 1.222, 
1.705, 2.336 respectively. It can be concluded that the overall financial soundness of the sample 
pharmaceuticals SPL and ISPIL are more satisfactory, BPL is satisfactory and OIL and LIL are not 
satisfactory i.e., worst leading to bankruptcy. It is observed from the Table-16 that the Z-Score of the 
selected pharmaceuticals is less stable (CV: SPL-28.78%, BPL-31.36%, ISPIL-7.890%, LIL-24.81% and 
OIL-31.87%). From the calculated value of t, it is found that there is a significant difference in Z-Score 
between industry average and LIL and OIL. On the other hand there lies an insignificant difference in 
Z-Score between industry average and SPL, BPL and ISPIL. 
 
9.  Ranking of the Selected Pharmaceuticals with respect to Financial Position: 
At this point we have tried to make the ranking of the sample pharmaceuticals in respect of liquidity, 
profitability and solvency position. For this purpose we have given score for every ratio in each category. 
For the best position showing pharmaceutical in respect of a particular ratio has given score 5 and for worst 
score 1 among the sample pharmaceuticals. The others are between score 4, 3 and 2 in accordance to their 
position. Then we have added the scores of all the ratios in each category for every pharmaceutical. Finally 
according to the score the ranking has made. The Table-17 shows that in case of liquidity SPL-14 made 
highest and OIL-10 made lowest score, the others (ISPIL-13, BPL-12 and LIL-11) are between them. The 
score shows that the SPL has best (Rank-I) liquidity position among the sample pharmaceuticals then ISPIL 
(Rank-II), BPL (Rank-III), LIL (Rank-IV) and OIL (Rank-V) respectively. In case of profitability SPL-28 
made highest and BPL-14 made lowest score, the others (ISPIL-27, OIL-21 and LIL -15) are between them. 
The score shows that the SPL has best (Rank-I) profitability position among the sample pharmaceuticals 
then ISPIL (Rank-II), OIL (Rank-III), LIL (Rank-IV) and BPL (Rank-V) respectively. In case of solvency 
SPL-9 made highest and LIL-2 made lowest score, the others (ISPIL-8, BPL-7 and OIL-4) are between 
them. The score shows that the SPL has best (Rank-I) solvency position among the sample pharmaceuticals 
then ISPIL (Rank-II), BPL (Rank-III), OIL (Rank-IV) and LIL (Rank-V) respectively. 
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10. Correlation, Probable Error and Limits of Correlation between the Liquidity, Profitability and 
Solvency Position of the Selected Pharmaceuticals: 
Of the several mathematical methods of computing correlation, the Karl Pearson’s method, popularly known 
as Pearsonian coefficient of correlation, is most widely used in practice and we have used this method in our 
study. The Table-18 shows that there is a moderate degree of positive [r = 0.631] correlation between the 
liquidity and profitability of the selected pharmaceuticals under the study. So, to earn more profit more 
investment in current assets is necessary in this industry. The calculated value of r [0.631] is more than the 
calculated value of P.E.r [0.182] but not more than the six times of the calculated value of P.E.r [1.090]. 
Therefore, the value of r is acceptable but not significant. The limits of the correlation should be 0.449 to 
0.812. 
There is a high degree of positive [r = 0.868] correlation between the liquidity and solvency of the selected 
pharmaceuticals under the study. So, adequate working capital is helpful to maintain financial solvency in 
this industry. The calculated value of r [0.868] is more than the calculated value of P.E.r [0.075] as well as 
more than the six times of the calculated value of P.E.r [0.447]. Therefore, the value of r is significant. The 
limits of the correlation should be 0.793 to 0.942. 
There is a moderate degree of positive [r = 0.658] correlation between the profitability and solvency of the 
selected pharmaceuticals under the study. So, financially more solvent companies are earning more profit in 
this industry, in another word the more the profitability, the more the solvency. The calculated value of r 
[0.658] is more than the calculated value of P.E.r [0.172] but not more than the six times of the calculated 
value of P.E.r [1.029]. Therefore, the value of r is acceptable but not significant. The limits of the correlation 
should be 0.486 to 0.829. So, the liquidity, profitability and solvency are highly interrelated to each other in 




From the above financial diagnosis it is found that the financial position and performance of the selected 
listed pharmaceutical companies in Bangladesh is in average position. Comparing among the selected 
pharmaceuticals, at the liquidity point of view SPL, ISPIL, BPL, LIL, and OIL hold better to worse position 
respectively; at the profitability point of view SPL, ISPIL, OIL, LIL and BPL hold better to worse position 
respectively and at the solvency point of view SPL, ISPIL, BPL, OIL and LIL, hold better to worse position 
respectively. So, financially SPL, BPL and ISPIL are in better position than LIL and OIL. The study also 
found that there is an interrelation among the liquidity, profitability and solvency determinant factors of the 
selected pharmaceuticals. As a result, to reach better solvency position, we have to invest more in this 
industry and usually we will get more profit than before. It is also necessary to invest adequate working 
capital, accelerate conversion of receivables and inventory into cash, increase of sales and redemption of debt 
for improving the financial strength of this industry. The Z-Score Model also showed that the SPL and ISPIL 
are out of bankruptcy risk, the BPL is also almost in safety range but LIL and OIL are not in a satisfactory 
position regarding bankruptcy risk. Therefore, it is an urgent need to find out, if any, the causes and 
limitations in against of further development of the sample pharmaceuticals. Study shows that besides the 
financial strength of the pharmaceutical industry, it faces some financial and non-financial limitations. These 
are: complicated procedure of opening Letter of Credit to import raw materials, imposing high tax to import 
sophisticated tools and machineries for production, inadequacy of fund, no professional distribution house, 
fixed mark-up system, limited capacity of drug testing laboratories, slow registration process and restrictions 
on patent right, contrary policy of the Government on producing some products, insufficiency of raw 
materials, lack of efficient people, lack of sound environment, lack of new entrepreneur, undue influence on 
tender process and vulnerability of environmental risk. So, steps should be taken for overcoming the financial 
and nonfinancial limitations of the pharmaceutical industries in Bangladesh. These steps are: the process of 
opening LC should be easier, tax rate should be reasonable, professional distribution house should be 
available by arranging more effective trading workshop, modernize the fix mark-up system, loan system 
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should be easier and sufficient, using modern technology in drug testing laboratories, minimize the period to 
collect raw materials and the cost of raw materials, modernize the patent right and Government should 
develop some policies for using the environment at best level. The limitations of the pharmaceutical industry 
in Bangladesh are highlighted in the above discussion and such type of limitations may be overcome by 
following the recommended corrective measures. Thus, in near future the pharmaceutical industry will reach 
better position in Bangladesh as well as abroad. 
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Category-A: Liquidity Ratios 
Table-01 (Insert the Table after 6.1.1): Current Ratio 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
Table-02 (Insert the Table after 6.1.2): Quick/Liquid/Acid-Test Ratio 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 











SD CV t-value 
SPL 1.440:1 1.260:1 1.460:1 1.387:1 1.130:1 0.110 7.947 4.033 
BPL 1.800:1 1.100:1 2.980:1 1.960:1 1.130:1 0.950 48.48 1.513 
ISPIL 0.694:1 0.832:1 0.730:1 0.752:1 1.130:1 0.072 9.548 (9.113) 
LIL 0.814:1 0.840:1 0.690:1 0.781:1 1.130:1 0.080 10.24 (7.552) 
OIL 0.706:1 0.825:1 0.782:1 0.771:1 1.130:1 0.060 7.782 (10.38) 











SD CV t-value 
SPL 0.790:1 0.630:1 0.610:1 0.677:1 0.512:1 0.099 14.56 2.888 
BPL 0.763:1 0.500:1 2.210:1 1.158:1 0.512:1 0.921 79.54 1.214 
ISPIL 0.170:1 0.323:1 0.265:1 0.253:1 0.512:1 0.078 30.68 (5.812) 
LIL 0.217:1 0.216:1 0.205:1 0.213:1 0.512:1 0.007 3.130 (77.97) 
OIL 0.192:1 0.313:1 0.282:1 0.262:1 0.512:1 0.063 23.94 (6.890) 
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Table-03 (Insert the Table after 6.1.3): Receivables Turnover [Times] 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
Table-04 (Insert the Table after 6.1.4): Inventory Turnover [Times] 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
 
Category-B: Profitability Ratios 
Table-05 (Insert the Table after 6.2.1): Profit Margin [%] 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
Table-06 (Insert the Table after 6.2.2): Asset Turnover [Times] 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 











SD CV t-value 
SPL 23.23 22.92 20.56 22.24 525.2 1.460 6.567 (596.6) 
BPL 7.199 7.958 7.014 7.390 525.2 0.500 6.786 (1793) 
ISPIL 4468 1760 1479 2569 525.2 1651 64.25 2.145 
LIL 14.56 23.85 12.26 16.89 525.2 6.136 36.33 (143.5) 
OIL 10.91 10.35 10.73 10.66 525.2 0.286 2.681 (3128) 











SD CV t-value 
SPL 2.960 2.720 2.750 2.810 4.471 0.131 4.655 (22.00) 
BPL 1.200 1.300 1.600 1.367 4.471 0.208 15.23 (25.85) 
ISPIL 9.150 11.02 12.85 11.01 4.471 1.850 16.81 6.119 
LIL 3.920 5.190 3.510 4.207 4.471 0.876 20.82 (0.522) 
OIL 2.480 3.334 3.077 2.964 4.471 0.438 14.78 (5.959) 











SD CV t-value 
SPL 17.00 17.00 19.00 17.67 8.158 1.155 6.536 14.26 
BPL 9.800 13.60 12.80 12.07 8.158 2.003 16.60 3.380 
ISPIL 3.550 4.110 3.850 3.837 8.158 0.280 7.303 (26.71) 
LIL 1.930 1.550 1.190 1.557 8.158 0.370 23.77 (30.89) 
OIL 3.940 7.507 5.539 5.662 8.158 1.787 31.56 (2.419) 











SD CV t-value 
SPL 0.760 0.710 0.760 0.743 1.020 0.029 3.928 (16.39) 
BPL 0.300 0.299 0.280 0.293 1.020 0.010 3.413 (125.4) 
ISPIL 2.160 2.310 2.290 2.253 1.020 0.081 3.604 26.28 
LIL 1.170 1.400 1.010 1.193 1.020 0.196 16.43 1.528 
OIL 0.480 0.699 0.677 0.619 1.020 0.120 19.46 (5.778) 
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Table-07 (Insert the Table after 6.2.3): Return on Asset [%] 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
Table-08 (Insert the Table after 6.2.4): Return on Common Stockholders’ Equity [%] 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
Table-09 (Insert the Table after 6.2.5): Earnings Per Share [EPS in Taka] 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
Table-10 (Insert the Table after 6.2.6): Price-Earnings Ratio [Times] 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 











SD CV t-value 
SPL 13.00 12.00 15.00 13.33 6.208 1.528 11.46 8.080 
BPL 2.960 4.100 3.600 3.553 6.208 0.571 16.08 (8.047) 
ISPIL 7.650 9.500 8.810 8.653 6.208 0.935 10.80 4.530 
LIL 2.260 2.170 1.200 1.877 6.208 0.588 31.32 (12.77) 
OIL 1.870 5.250 3.749 3.623 6.208 1.694 46.74 (2.644) 











SD CV t-value 
SPL 19.00 18.00 21.00 19.33 13.26 1.528 7.901 6.888 
BPL 4.360 5.800 5.900 5.353 13.26 0.862 16.10 (15.89) 
ISPIL 16.98 24.40 24.37 21.92 13.26 4.275 19.51 3.508 
LIL 7.840 7.830 5.130 6.933 13.26 1.562 22.53 (7.016) 
OIL 6.751 18.61 12.91 12.76 13.26 5.931 46.49 (0.147) 











SD CV t-value 
SPL 218.6 154.5 156.6 176.6 56.52 36.42 20.63 5.711 
BPL 3.080 4.330 4.130 3.847 56.52 0.672 17.46 (135.7) 
ISPIL 31.19 48.09 54.70 44.66 56.52 12.12 27.15 (1.694) 
LIL 48.14 51.25 34.93 44.77 56.52 8.665 19.35 (2.348) 
OIL 6.750 18.61 12.87 12.74 56.52 5.931 46.54 (12.78) 











SD CV t-value 
SPL 11.19 26.60 18.75 18.85 24.33 7.706 40.89 (1.234) 
BPL 19.12 38.73 37.72 31.86 24.33 11.04 34.67 1.180 
ISPIL 25.22 20.71 28.38 24.77 24.33 3.855 15.56 0.196 
LIL 11.00 28.24 45.81 28.35 24.33 17.41 61.39 0.400 
OIL 13.37 8.080 32.09 17.85 24.33 12.62 70.69 (0.891) 
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Table-11 (Insert the Table after 6.2.7): Payout Ratio [%] 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
Category-C: Solvency Ratios 
Table-12 (Insert the Table after 6.3.1): Debt to Total Assets Ratio [%] 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
 
Table-13 (Insert the Table after 6.3.2): Times Interest Earned [Times] 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
Table-14 (Insert the Table after 7): Sustainable Growth Rate [%] 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
Table-15 (Insert the Table after 8): Ratios for Testing Financial Soundness. 











SD CV t-value 
SPL 45.74 48.53 41.52 45.26 48.67 3.529 7.797 (1.673) 
BPL 48.70 69.28 36.32 51.33 48.67 16.65 32.43 0.277 
ISPIL 73.74 51.98 50.27 58.66 48.67 13.08 22.23 1.323 
LIL 36.35 34.15 42.94 37.81 48.67 4.574 12.10 (4.119) 
OIL 0.000 53.73 97.13 50.29 48.67 48.66 96.76 (0.057) 











SD CV t-value 
SPL 30.00 34.00 25.00 29.67 53.81 4.509 15.20 (9.276) 
BPL 30.97 29.50 45.30 35.26 53.81 8.729 24.76 (3.683) 
ISPIL 57.54 63.27 64.34 61.72 53.81 3.656 5.925 3.743 
LIL 72.00 72.49 79.69 74.73 53.81 4.305 5.761 8.413 
OIL 70.92 67.27 64.93 67.71 53.81 3.019 4.459 7.971 











SD CV t-value 
SPL 8.270 6.310 7.320 7.300 5.657 0.980 13.43 2.904 
BPL 2.600 3.860 3.990 3.483 5.657 0.768 22.04 (4.904) 
ISPIL 17.36 12.40 12.99 14.25 5.657 2.709 19.01 5.494 
LIL 1.500 1.500 1.300 1.433 5.657 0.116 8.060 (63.33) 
OIL 1.402 2.180 1.872 1.818 5.657 0.392 21.55 (16.97) 











SD CV t-value 
SPL 10.31 9.265 12.28 10.62 6.451 1.531 14.42 4.717 
BPL 2.237 1.782 3.760 2.593 6.451 1.036 39.95 (6.450) 
ISPIL 4.460 11.72 12.12 9.433 6.451 4.312 45.71 1.198 
LIL 4.990 5.160 2.930 4.360 6.451 1.241 28.47 (2.917) 
OIL 6.750 8.611 0.371 5.244 6.451 4.322 82.41 (0.484) 
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Ratios SPL BPL ISPIL LIL OIL Year 
Working Capital 
To Total Assets 
(In Time) 
0.110 0.108 (0.170) (0.085) (0.092) 2006-07 
0.070 0.018 (0.090) (0.069) (0.059) 2007-08 
0.090 0.230 (0.140) (0.150) (0.084) 2008-09 
0.090 0.119 (0.133) (0.101) (0.078) Mean 
0.020 0.106 0.040 0.043 0.017 SD 
22.22 89.55 (30.31) (42.35) (21.97) CV 
Retained Earnings 
To Total Assets 
(In Time) 
0.330 0.270 0.020 0.106 0.303 2006-07 
0.340 0.270 0.040 0.099 0.258 2007-08 
0.410 0.220 0.080 0.077 0.245 2008-09 
0.360 0.253 0.047 0.094 0.269 Mean 
0.044 0.029 0.031 0.015 0.031 SD 
12.11 11.41 65.45 16.10 11.35 CV 
Earnings Before 
Interest and Taxes 
To 
Total Assets  
(In Time) 
0.190 0.050 0.100 0.087 0.066 2006-07 
0.170 0.065 0.110 0.091 0.098 2007-08 
0.220 0.058 0.110 0.065 0.082 2008-09 
0.193 0.058 0.107 0.081 0.082 Mean 
0.026 0.008 0.006 0.014 0.016 SD 
13.61 13.02 5.412 17.28 19.51 CV 
Market Value of 
Equity To Total 
Debt (In Time) 
4.630 1.820 3.090 0.323 0.355 2006-07 
8.580 4.830 2.760 0.818 0.639 2007-08 
10.73 2.610 3.590 0.592 1.889 2008-09 
7.980 3.087 3.147 0.578 0.961 Mean 
3.094 1.561 0.418 0.248 0.816 SD 
38.77 50.56 13.28 42.89 84.92 CV 
Sales To Total 
Assets (In Time) 
0.720 0.300 1.990 1.097 0.477 2006-07 
0.650 0.270 2.050 1.354 0.708 2007-08 
0.740 0.240 2.120 0.865 0.690 2008-09 
0.703 0.270 2.053 1.105 0.625 Mean 
0.047 0.030 0.065 0.245 0.129 SD 
6.720 11.11 3.171 22.13 20.56 CV 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
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Table-16 (Insert the Table after 8): Analysis of Z score. 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
Table-17 (Insert the Table after 9): Ranking of the Selected Pharmaceuticals with respect to Financial 
Position (Based on Mean Ratios). 
Ratios/Basis 
Name of The Pharmaceuticals 
SPL BPL ISPIL LIL OIL 
Liquidity Ratios:  
Current Ratio 4 5 1 3 2 
Liquid Ratio 4 5 2 1 3 
Receivables Turnover 4 1 5 3 2 
Inventory Turnover 2 1 5 4 3 
Total Score [Liquidity] 14 12 13 11 10 
Rank I III II IV V 
Profitability Ratios:  
Profit Margin 5 4 2 1 3 
Asset Turnover 3 1 5 4 2 
Return on Asset 5 2 4 1 3 
Return on Common 
Stockholders’ Equity 4 1 5 2 3 
Earnings Per Share 5 1 3 4 2 
Price-Earnings Ratio 4 1 3 2 5 
Payout Ratio 2 4 5 1 3 
Total Score [Profitability] 28 14 27 15 21 
Rank I V II IV III 
Solvency Ratios:  
Debt to Total Assets Ratio 5 4 3 1 2 
Times Interest Earned 4 3 5 1 2 
Total Score [Solvency] 9 7 8 2 4 
Rank I III II V IV 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 










SD CV t-value 
SPL 4.719 6.919 8.586 6.741 3.447 1.940 28.78 2.941 
BPL 2.065 3.782 2.581 2.809 3.447 0.881 31.36 (1.253) 
ISPIL 3.998 4.017 4.581 4.199 3.447 0.331 7.890 3.932 
LIL 1.624 2.201 1.363 1.729 3.447 0.429 24.81 (6.937) 
OIL 1.222 1.705 2.336 1.754 3.447 0.559 31.87 (5.247) 
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Table-18 (Insert the Table after 10): Coefficient of Correlation (r), Probable Error (P.E.r) and Limits of 
Correlation (Based on Scores) between the Liquidity (L), Profitability (P) and Solvency (S) Position of the 
Selected Pharmaceuticals. 
Name of The 
Pharmaceuticals 
Score L and P L and S P and S 




















































BPL 12 14 7 
ISPIL 13 27 8 
LIL 11 15 2 
OIL 10 21 4 
Source: Annual Reports and Official Records of the Selected Pharmaceuticals. 
 
List of Pharmaceuticals under Study 
 
Name of The Pharmaceuticals Acronym 
SQUARE PHARMACEUTICALS LTD. SPL 
BEXIMCO PHARMACEUTICALS LTD. BPL 
The IBN SINA Pharmaceutical Industry Ltd. ISPIL 
Libra Infusions Limited LIL 
Orion Infusion Ltd. OIL 
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